화학업체와 학교 및 기관의 구인/구직 소식을 살펴보실 수 있습니다.
게시물 등록에 대한 문의사항은 오민영 메일로 해주시기 바랍니다.

※ 게시물 등록절차 : 로그인후 글 작성(비공개) 담당자에게 자동통보 확인 후 게시물승인(공개)
※ 주의사항1 : 업체명이 없는 (예:헤드헌팅) 등록 글은 통보 없이 삭제 처리됩니다.
※ 주의사항2 : 게시물 승인이후 수정 하실 경우 다시 비공개로 전환됩니다.

출연연 NIH Medicinal Chemistry Postdoctoral Fellowship for Anti-cancer Drug Discovery
2017.02.14 조회 수 : 856 마감일 : 2017.04.30

Title: Medicinal Chemistry Postdoctoral Fellowship at NCI, NIH


A postdoctoral fellowship in the field of medicinal chemistry is immediately available to carry out structure-based drug design and hit-to-lead optimization on several promising hits against polo-like kinase 1 (Plk1).  Plk1 is an attractive anti-cancer therapeutic target, whose upregulated activity is tightly associated with aggressiveness and poor prognosis for a wide spectrum of human cancers. We performed high throughput screening campaigns at the at the National Center for Advancing Translational Sciences (NCATS) (, and isolated a new class of several anti-Plk1 small molecule compounds, whose cocrystal structures have been determined lately. In an effort to discover novel Plk1-targeted anti-cancer therapeutic agents, we have developed an NCI’s multifaceted collaboration project by bringing together various expertise, including medicinal chemistry optimization, X-ray crystallography, in silico modeling, pharmacokinetics/pharmacodynamics, and mouse tumorigenesis studies. Once appointed, the fellow will primarily work in the synthetic chemistry lab at NCATS under the direct guidance of Dr. David Maloney (, the medicinal chemistry leader at NCATS, and Dr. Kyung Lee ( in the Laboratory of Metabolism, NCI, and will have an opportunity to interact with other collaboration teams involved in this interdisciplinary project.

Applicants should have (or expected to receive) a Ph.D. or its equivalent at the time of joining the lab or have achieved the degree less than 3 years ago. Fellows who have an expertise in medicinal chemistry optimization of small molecule inhibitors or X-ray crystallography are encouraged to apply. Salary starts at $51,900 with full health insurance for fellows with no prior postdoctoral training.

To apply, please send CV and three names of references to Dr. Kyung Lee (


Employer Name: National Cancer Institute, NIH.

Position Location: 9000 Rockville Pike, Bethesda, MD 20892, U. S. A.


Selected Publications:

1) Yun, S. -M. et al., 2009. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat. Str. & Mol. Biol. 16:876.

2) Liu, F. et al., 2011. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel.  Nat. Chem. Biol. 7:595.

3) Liu, F. et al., 2012. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using Oxime-based diversification. ACS Chem. Biol. 7:805.

4) Liu, F. et al., 2012. Peptoid-peptide hybrid ligands targeting the polo-box domain of polo-like kinase 1. Chembiochem. 13:1291.

5) Qian W. -J. et al., 2012. Non-proteinogenic amino            acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo-box domain (PBD) of polo-like kinase 1 (Plk1). Bioorg Med Chem Lett. 22:7306.

6) Qian, W. -J. et al., 2013. Effects on Polo-like Kinase 1 Polo-box Domain Binding Affinities of Peptides Incurred by Structural Variation at the Phosphoamino Acid Position. Bioorg. & Med. Chem. 21: 3996.

7) Qian, W. -J. et al., 2014. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells. Biopolymers 102:444.

8) Qian, W. -J. et al., 2015. Neighbor-directed Histidine N(τ)–Alkylation: A Route to Imidazolium-containing Phosphopeptide Macrocycles. Biopolymers, 104:663

9) Lee, K. S. et al., 2015. Recent advances and new strategies in targeting Plk1 for anticancer therapy. Trends in Pharmacological Sciences. 36:858 (review).